Risk of Central Serous Chorioretinopathy in Male Androgen Abusers
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Risk of Central Serous Chorioretinopathy in Male Androgen Abusers. / Subhi, Yousif; Windfeld-Mathiasen, Josefine; Horwitz, Anna; Horwitz, Henrik.
In: Ophthalmology and Therapy, Vol. 12, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Risk of Central Serous Chorioretinopathy in Male Androgen Abusers
AU - Subhi, Yousif
AU - Windfeld-Mathiasen, Josefine
AU - Horwitz, Anna
AU - Horwitz, Henrik
N1 - Publisher Copyright: © 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - Introduction: Male gender is an important risk factor of central serous chorioretinopathy (CSC), and studies have explored the pathophysiological role of androgens in CSC with conflicting results. In this study, we shed light on this hot topic by exploring the risk of CSC in a large cohort of male androgen abusers. Methods: This study included male androgen abusers identified through a nationwide anti-doping test program across Danish fitness centers from January 3 2006 to March 1 2018. For each case, we randomly sampled ten male controls using Danish nationwide registries. These controls were matched in age and date. Cases and controls were followed until May 16 2018. Data on diagnoses were extracted using the Danish National Registry of Patients using ICD-10 codes to identify cases with CSC. Results: We included 1189 cases and 11,890 controls. Mean age at the time of doping sentence was 27.4 ± 6.9 years, and mean length of follow-up was 15.8 ± 3.6 years. We identified no cases of CSC in androgen abusers, and five cases of CSC in the control cohort. The difference between groups was not statistically significant (P = 1.0). Conclusions: Male androgen abusers were not at increased risk of CSC. Considering the lack of any signal in this large study, we speculate that if male androgen plays any direct role in the pathophysiology of CSC, its role may be subtle at best.
AB - Introduction: Male gender is an important risk factor of central serous chorioretinopathy (CSC), and studies have explored the pathophysiological role of androgens in CSC with conflicting results. In this study, we shed light on this hot topic by exploring the risk of CSC in a large cohort of male androgen abusers. Methods: This study included male androgen abusers identified through a nationwide anti-doping test program across Danish fitness centers from January 3 2006 to March 1 2018. For each case, we randomly sampled ten male controls using Danish nationwide registries. These controls were matched in age and date. Cases and controls were followed until May 16 2018. Data on diagnoses were extracted using the Danish National Registry of Patients using ICD-10 codes to identify cases with CSC. Results: We included 1189 cases and 11,890 controls. Mean age at the time of doping sentence was 27.4 ± 6.9 years, and mean length of follow-up was 15.8 ± 3.6 years. We identified no cases of CSC in androgen abusers, and five cases of CSC in the control cohort. The difference between groups was not statistically significant (P = 1.0). Conclusions: Male androgen abusers were not at increased risk of CSC. Considering the lack of any signal in this large study, we speculate that if male androgen plays any direct role in the pathophysiology of CSC, its role may be subtle at best.
KW - Anabolic steroids
KW - Androgen abusers
KW - Central serous chorioretinopathy
KW - Cohort study
KW - Testosterone
U2 - 10.1007/s40123-023-00658-4
DO - 10.1007/s40123-023-00658-4
M3 - Journal article
C2 - 36692812
AN - SCOPUS:85146803470
VL - 12
JO - Ophthalmology and Therapy
JF - Ophthalmology and Therapy
SN - 2193-8245
ER -
ID: 334659040